Skip Navigation


Carcinogenesis Advance Access originally published online on February 4, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
25/7/1129    most recent
bgh107v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (31)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Pennati, M.
Right arrow Articles by Zaffaroni, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pennati, M.
Right arrow Articles by Zaffaroni, N.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 25, No. 7, 1129-1136, July 2004
Carcinogenesis vol.25 no.7 © Oxford University Press 2004; all rights reserved.


ARTICLE

Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo

Marzia Pennati1, Mara Binda1, Michelandrea De Cesare1, Graziella Pratesi1, Marco Folini1, Lorenzo Citti2, Maria Grazia Daidone1, Franco Zunino1 and Nadia Zaffaroni1,3

1 Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, I-20133 Milan and 2 Istituto di Fisiologia Clinica-CNR, Pisa, Italy

3 To whom correspondence should be addressed Email: nadia.zaffaroni{at}istitutotumori.mi.it

The ability of melanoma cells to evade engagement of apoptosis plays a significant role in their resistance to chemotherapy. In an attempt to lower the apoptotic threshold of melanoma cells as a possible strategy to increase their drug sensitivity, we generated a hammerhead ribozyme to down-regulate the expression of the anti-apoptotic protein survivin. The JR8 human melanoma cell line was stably transfected with the active ribozyme RZsurv (targeting the 3' end of the GUC294 triplet in the exon 3 of the survivin mRNA) or the catalytically inactive ribozyme mutRZsurv (carrying a mutation in the catalytic core of RZsurv). Two polyclonal cell populations expressing the active (JR8/RZsurv) or the mutant (JR8/mutRZsurv) ribozyme were selected for the study. JR8/RZsurv cells were characterized by a markedly lower survivin protein level than JR8 parental cells, whereas a negligible reduction in survivin expression was observed in JR8/mutRZsurv cells. JR8/RZsurv cells showed a significantly increased sensitivity to the topoisomerase-I inhibitor topotecan (as detected by clonogenic cell survival) compared with JR8/mutRZsurv cells. Moreover, the extent of drug-induced apoptosis (in terms of percentage of apoptotic nuclei and level of caspase-9 and caspase-3 catalytic activity) was significantly greater in JR8/RZsurv than in JR8/mutRZsurv cells. Finally, an increased antitumor activity of oral topotecan was observed in JR8/RZsurv cells grown as xenograft tumors in athymic nude mice compared with JR8/mutRZsurv cells. These results demonstrate that attenuation of survivin expression renders human melanoma cells more susceptible to topotecan-induced apoptosis and more responsive to in vivo treatment, and support the concept that survivin is an attractive target for new therapeutic interventions in melanoma.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Cancer Prevention ResearchHome page
N. Bhatnagar, X. Li, Y. Chen, X. Zhou, S. H. Garrett, and B. Guo
3,3'-Diindolylmethane Enhances the Efficacy of Butyrate in Colon Cancer Prevention through Down-Regulation of Survivin
Cancer Prevention Research, June 1, 2009; 2(6): 581 - 589.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Thomas, T. Liu, M. A. Cotter, S. R. Florell, K. Robinette, A. N. Hanks, and D. Grossman
Melanocyte Expression of Survivin Promotes Development and Metastasis of UV-Induced Melanoma in HGF-Transgenic Mice
Cancer Res., June 1, 2007; 67(11): 5172 - 5178.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. Pennati, M. Folini, and N. Zaffaroni
Targeting survivin in cancer therapy: fulfilled promises and open questions
Carcinogenesis, June 1, 2007; 28(6): 1133 - 1139.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
X. Huang and B. Guo
Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells.
Cancer Res., September 15, 2006; 66(18): 9245 - 9251.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
X.-F. Che, C.-L. Zheng, S. Owatari, M. Mutoh, T. Gotanda, H.-C. Jeung, T. Furukawa, R. Ikeda, M. Yamamoto, M. Haraguchi, et al.
Overexpression of survivin in primary ATL cells and sodium arsenite induces apoptosis by down-regulating survivin expression in ATL cell lines
Blood, June 15, 2006; 107(12): 4880 - 4887.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
F. Paduano, R. Villa, M. Pennati, M. Folini, M. Binda, M. G. Daidone, and N. Zaffaroni
Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells
Mol. Cancer Ther., January 1, 2006; 5(1): 179 - 186.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. L. Bevins and S. G. Zimmer
It's About Time: Scheduling Alters Effect of Histone Deacetylase Inhibitors on Camptothecin-Treated Cells
Cancer Res., August 1, 2005; 65(15): 6957 - 6966.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Krysan, H. Dalwadi, S. Sharma, M. Pold, and S. Dubinett
Cyclooxygenase 2-Dependent Expression of Survivin Is Critical for Apoptosis Resistance in Non-Small Cell Lung Cancer
Cancer Res., September 15, 2004; 64(18): 6359 - 6362.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.